A phase I clinical trial of the mTOR inhibitor everolimus in combination with oral topotecan for patients with recurrent and advanced endometrial cancer
Abu-Khalaf M, Santin A, Ratner E, Silasi D, ElSahwi K, Baker L, Luther M, Azodi M, Rutherford T, Schwartz P. A phase I clinical trial of the mTOR inhibitor everolimus in combination with oral topotecan for patients with recurrent and advanced endometrial cancer. Gynecologic Oncology 2011, 120: s97-s98. DOI: 10.1016/j.ygyno.2010.12.232.Peer-Reviewed Original Research